IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical stage immunotherapy company, announced today that it will hold
a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m.
ET. This call will provide an update on its ongoing phase 2 clinical
trials with Merck’s Keytruda® in diffuse large B-cell lymphoma (DLBCL).
Financial analysts are invited to join the conference call by dialing
(866) 211-2304 (U.S. and Canada) or (647) 689-6600 (International) using
the conference ID: 9685423
Other interested parties will be able to access the live audio webcast
at this link: https://ir.imv-inc.com/events-and-presentations.
The webcast will be recorded and made available on the IMV website for
30 days following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies
that programs targeted T cells in vivo. It has demonstrated
the potential for industry-leading targeted, persistent, and durable T
cell activation. IMV believes this MOA is key to generating durable
solid tumor regressions. DPX-Survivac consists of survivin-based peptide
antigens formulated in IMV’s proprietary DPX drug development platform.
DPX-Survivac is believed to work by eliciting a cytotoxic T cell immune
response against cells presenting survivin peptides.
Survivin, recognized by the National Cancer Institute (NCI) as a
promising tumor-associated antigen, is broadly over-expressed in most
cancer types, and plays an essential role in antagonizing cell death,
supporting tumor-associated angiogenesis, and promoting resistance to
anti-cancer therapies. IMV has identified over 15 cancer indications in
which the over-expression of survivin can be targeted by DPX-Survivac.
DPX-Survivac has received Fast
Track designation from the U.S. Food and Drug Administration (FDA)
as maintenance therapy in advanced ovarian cancer, as well as orphan
drug designation status from the U.S. FDA and the European
Medicines Agency (EMA) in the ovarian cancer indication. It is
currently being evaluated in multiple Phase 1b/2 clinical trials.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. However,
they should not be regarded as a representation that any of the plans
will be achieved. Actual results may differ materially from those set
forth in this press release due to risks affecting the Corporation,
including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks and
uncertainties include, but are not limited to, our ability to access
capital, the successful and timely completion of clinical trials, the
receipt of all regulatory approvals and other risks detailed from time
to time in our ongoing quarterly filings and annual information form.
Investors are cautioned not to rely on these forward-looking statements
and are encouraged to read IMV’s continuous disclosure documents,
including its current annual information form, as well as its audited
annual consolidated financial statements which are available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov/edgar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005531/en/
Copyright Business Wire 2019